Thermo Fisher Board Clears New $5B Buyback, Replacing $1B Remaining Authorization
TMO sits 58% above its 52-week low of $435.27 on light trading volume (0.2× avg).
Summary
Thermo Fisher's board authorized up to $5 billion of share repurchases with no expiration date, executed in the open market or through negotiated transactions. The new program replaces the prior authorization, which had $1 billion left. At a market value near $254 billion, $5 billion is roughly 2% of the company — meaningful but not transformative, and the stock is already trading near its 52-week high. The authorization follows the October 21 third-quarter report: adjusted EPS of $6.68 versus $6.40 consensus and sales of $12.14 billion, up 9% with 6% organic growth, plus raised 2026 adjusted EPS guidance of $25.13-$25.43 and sales guidance of $47.70-$48.20 billion. Shares were up about 2% Friday. The buyback is a capital-return signal rather than a thesis change; the next hard data point is fourth-quarter results, which the company has not yet dated.
At the time of this announcement, TMO was trading at $686.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $254.2B. The 52-week trading range was $435.27 to $712.17. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.